SYN-004 (ribaxamase) prevents New Onset Clostridium difficile Infection by Protecting the Integrity Gut Microbiome in a Phase 2b Study

Por Kokai-Kun, John, Roberts, Tracey, Coughlin, Olivia, Whalen, Heidi, Le, Charles, Da Costa, Christopher, Sliman, Joseph
Publicado no Open Forum Infect Dis (2017)

The Oral β-Lactamase SYN-004 (Ribaxamase) Degrades Ceftriaxone Excreted into the Intestine in Phase 2a Clinical Studies

Por Kokai-Kun, John F., Roberts, Tracey, Coughlin, Olivia, Sicard, Eric, Rufiange, Marianne, Fedorak, Richard, Carter, Christian, Adams, Marijke H., Longstreth, James, Whalen, Heidi, Sliman, Joseph
Publicado no Antimicrob Agents Chemother (2017)